You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Funded Evidence-Informed Regimens

Drug and regimen monographs and information sheets for patients provide information on dosing and administering cancer treatment protocols. They are for general reference and are not meant to replace prescribing information or physician recommendations.

If you have questions about ST-QBP funding on our website, please visit our Frequently Asked Questions page.

Find enhanced Regimen Patient Information Sheets, created in collaboration with patient and family advisors.

Regimens

14 Items
Cancer Type: Hematologic, Lymphoma - T-cell, Rare Diseases     
Intent: Palliative
Drugs Used:
alemtuzumab (Compassionate)
Sep 2019
Cancer Type: Hematologic, Leukemia - Chronic Lymphocytic (CLL)     
Intent: Palliative
Drugs Used:
alemtuzumab (Compassionate),
riTUXimab (Unfunded)
Dec 2017
Cancer Type: Hematologic, Leukemia - Chronic Lymphocytic (CLL)     
Intent: Palliative
Drugs Used:
alemtuzumab (Compassionate)
Updated
Nov 2019
Cancer Type: Gastrointestinal, Neuroendocrine (GI)     
Intent: Palliative
Funding:
ODB - General Benefit
    capecitabine
Drugs Used:
temozolomide (Unfunded)
May 2019
Cancer Type: Hematologic, Leukemia - Chronic Lymphocytic (CLL)     
Intent: Palliative
Jun 2019
Cancer Type: Sarcoma, Ewing's     
Intent: Palliative
Drugs Used:
temozolomide (Unfunded),
Oct 2017
Cancer Type: Hematologic, Leukemia - Chronic Myeloid (CML)     
Intent: Palliative
Funding:
Exceptional Access Program
    ponatinib - For the treatment of Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia, according to specific clinical criteria
Jun 2019
Cancer Type: Hematologic, Leukemia - Acute Lymphoblastic (ALL)     
Intent: Curative, Palliative
Funding:
Exceptional Access Program
    ponatinib - For the treatment of Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL), according to specific clinical criteria
Jun 2019
Cancer Type: Skin, Melanoma     
Intent: Palliative
Drugs Used:
temozolomide (Unfunded)
Jun 2019
Cancer Type: Central Nervous System     
Intent: Palliative
Funding:
ODB Limited Use
    temozolomide - Recurrent or progressive glioblastoma multiforme or anaplastic astrocytoma
Jun 2019
Cancer Type: Central Nervous System     
Intent: Adjuvant
Funding:
ODB Limited Use
    temozolomide - Newly diagnosed glioblastoma multiforme (concurrent radiotherapy then maintenance)
Jun 2019
Cancer Type: Gastrointestinal, Neuroendocrine (GI), Lung, Neuroendocrine (Lung)     
Intent: Palliative
Drugs Used:
temozolomide (Unfunded)
May 2019